What Adragos Pharma does

Adragos Pharma is a Germany-headquartered global contract development and manufacturing organization (CDMO) specializing in sterile injectables, oral solid dosage forms, semi-solids, and non-sterile liquids. Founded in 2020 as part of the Plange Group, the company has built a seven-facility network spanning Germany, France, Norway, Switzerland, Greece, and Japan, with capabilities spanning prefilled syringe filling (150 million units annual capacity), vial filling (6 million units), tablet production (2 billion units), Blow-Fill-Seal IV bag technology, lyophilized vial manufacturing, and high-potency active pharmaceutical ingredient (HPAPI) handling. Each facility operates under multi-jurisdictional regulatory certifications including EU GMP, U.S. FDA, Japan PMDA, and Brazil ANVISA, enabling Adragos to serve as a primary or secondary supply source across the three largest pharmaceutical markets simultaneously.

The company's technology stack is rooted in acquired industrial assets rather than proprietary R&D, with capabilities inherited from the Lamda Labs, Sanofi Kawagoe, Fresenius Kabi Halden, Baccinex, and Sanofi Maisons-Alfort facility transactions completed between 2023 and 2026. Technical differentiation is concentrated in complex sterile formats (BFS IV bags, prefilled syringes, lyophilized vials) and HPAPI handling, which command premium pricing relative to commodity oral solid dose manufacturing. Adragos's portfolio is positioned to capture both branded and generic injectable supply contracts as big-pharma players continue divesting captive manufacturing capacity.

Adragos operates a project-based B2B revenue model typical of mid-tier CDMOs, monetizing through long-term commercial supply agreements, technology transfer fees, and development contracts. Anchor customers include Fresenius Kabi (via a multi-year supply agreement tied to the Halden acquisition), Towa Pharmaceutical (Japan), Colonis Pharma, and emerging biotech clients such as Igyxos and Roma Pharmaceuticals. The company is privately held under the Plange Group with FSN Capital Partners as institutional investor. Go-to-market emphasizes geographic proximity to regional pharma clusters, regulatory multi-jurisdictional coverage, and capacity for both large commercial-scale production and smaller specialty batches.

Name

Adragos Pharma

Legal name

Adragos Pharma GmbH

Website

https://adragos-pharma.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

251–500 employees

Short description

Adragos Pharma is a Munich-headquartered global CDMO operating seven sterile injectable, oral solid, and specialty manufacturing facilities across Europe and Japan. It serves branded pharma, generic manufacturers, and biotechs with prefilled syringes, vials, BFS IV bags, and HPAPI capabilities.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Oral Solid Dose (OSD) Generics (HLAIABAD)

Keywords

• Pharmaceutical contract manufacturing
• Drug development services
• Sterile injectables manufacturing
• Aseptic fill-finish services
• Lyophilization manufacturing services

Headquarters

HQ city

München

HQ country

Germany

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D

Revenue model

1. Contract Development Services: Full spectrum of drug development services including formulation development, analytical development, clinical development, and HPAPI expertise. Services provided from early-stage development through scale-up to commercial production.
2. Clinical Manufacturing Services: GMP-compliant clinical trial manufacturing including preclinical material preparation, aseptic filling, and lyophilization services for clinical supply.
3. Commercial Manufacturing Services: Large-scale manufacturing of sterile liquids (prefilled syringes, vials, ampoules, IV bags), non-sterile liquids, semi-solids, oral solids, and suppositories for commercial supply.
4. Integrated Services: Additional services including visual inspection, pharmaceutical packaging, controlled drugs handling, supply chain planning, drug stability testing, cold chain management, and regulatory services.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels10 records

Core offering

Adragos Pharma is a global Contract Development and Manufacturing Organization (CDMO) providing end-to-end pharmaceutical services spanning drug development, clinical manufacturing, and commercial manufacturing. Its offering covers formulation, analytical, and clinical development including HPAPI expertise, GMP-compliant clinical trial manufacturing, and large-scale commercial production of sterile liquids (prefilled syringes, vials, ampoules, IV bags), non-sterile liquids, oral solids, semi-solids, and suppositories, complemented by visual inspection, packaging, cold chain, regulatory, and out-licensing services across seven facilities in Europe and Japan.

Product overview

Adragos Pharma is a global Contract Development and Manufacturing Organization (CDMO) headquartered in Munich, Germany, providing comprehensive end-to-end CDMO services for pharmaceutical and biotech companies. Their integrated offering spans from drug development (formulation, analytical, clinical development, HPAPI expertise) through clinical manufacturing (preclinical material, aseptic filling, lyophilisation) to commercial manufacturing. The commercial manufacturing portfolio includes sterile liquids (prefilled syringes, vials, ampoules, IV bags), non-sterile liquids (oral solutions, drops, suspensions), semi-solids (creams, ointments, gels), oral solids, and suppositories. Supporting services include visual inspection, pharmaceutical packaging, controlled drugs handling, supply chain planning, drug stability testing, cold chain management, regulatory services, and out licensing. With seven global manufacturing and development facilities across Europe (Athens, Halden, Jura, Livron, Leipzig, Maisons-Alfort) and Japan (Kawagoe), plus regional offices in Munich and Tokyo, Adragos serves clients throughout Europe, Japan, and North America.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Development Services Comprehensive pharmaceutical CDMO development services covering formulation development, analytical development, clinical development, and HPAPI expertise for both small and large molecules. Targeted at pharmaceutical and biotech companies seeking outsourced development through clinical phases and on to commercial manufacturing.
• Clinical Manufacturing Services End-to-end clinical manufacturing services from feasibility studies and pre-clinical material preparation through GMP-compliant production, including aseptic filling and lyophilisation. Serves biotech and pharmaceutical clients preparing clinical trial supplies for sterile and lyophilised products.
• Commercial Manufacturing Services Large-scale commercial manufacturing delivered across five European facilities and one Japanese facility, covering sterile and non-sterile liquids, oral solids, semi-solids, and biologicals. Serves pharmaceutical companies requiring commercial supply of finished dosage forms.
• Sterile Injectables Manufacturing - Prefilled Syringes and Vials High-speed aseptic filling of prefilled syringes and liquid/lyophilised vials at the Maisons-Alfort facility in France, with up to 150 million prefilled syringe units per year capacity and up to 6 million vials per year including lyophilised formats. Serves pharma clients requiring large-scale European sterile injectables supply.
• IV Bags and Plastic Ampoules (Blow-Fill-Seal) Manufacturing Manufacture of sterile IV bags from 50 mL to 5,000 mL and plastic ampoules using Blow-Fill-Seal (BFS) technology at the Halden facility in Norway, with IV bag batch sizes up to 15,000 L. Targets pharmaceutical clients needing high-volume sterile liquids and parenteral packaging.
• Value-Added Medicines Development with HPAPI Expertise Specialised pharmaceutical development services at the Athens development centre covering Value-Added Medicines (VAMs), generic, and NCE development with HPAPI capabilities and EU GMP certification for handling controlled substances including clonazepam, phenobarbital, and fentanyl. Serves generic and specialty pharma companies needing differentiated formulations.
• Tablets and Sterile Ampoules Manufacturing (Kawagoe) Manufacture of oral solid tablets (up to 2 billion annually) and sterile ampoules (up to 30 million units annually) with integrated visual inspection and packaging services at the Kawagoe facility in Japan, supported by PMDA certification and one of Japan's largest cold storage warehouses. Serves Japanese pharmaceutical clients requiring oral solid and sterile ampoule manufacturing with full service.
• Sterile Liquids Ampoules and Suppositories Manufacturing (Livron) Sterile liquid ampoules and suppository manufacturing with over 100 years of operating experience at the Livron facility in France, handling over 100 molecules with integrated stability studies, narcotics handling, and analytical testing under EU GMP (ANSM, ANSES) and KFDA certification. Serves pharmaceutical clients requiring traditional European sterile ampoule and suppository supply.
• Semi-Solids and Non-Sterile Liquids Manufacturing (Leipzig) Manufacture of semi-solid dosage forms (creams, gels, ointments, healing pastes) and non-sterile liquids (oral solutions, drops, suspensions, emulsions, disinfection products) at the Leipzig facility in Germany, with over 100 years of experience and EU GMP certification for human and veterinary medicinal products under the German Medicines Act.
• Clinical and Commercial Small-Batch Sterile Manufacturing (Jura) GMP-certified clinical and commercial manufacturing of lyophilised and liquid sterile (bio)pharmaceuticals in small batches with no minimum lot size requirement at the Jura facility in Switzerland, supporting production from as little as 200-300 mL of API through commercial supply. Serves biotech, orphan-drug, and specialty pharma clients requiring low-volume lyophilised or liquid sterile production.
• Automated Visual Inspection Services Automated and semi-automatic visual inspection for prefilled syringes (up to 600 syringes/minute) and vials (up to 100 vials/minute) ensuring consistent product quality at scale. Service is integrated with sterile manufacturing across facilities and is also offered for client-supplied product.
• Pharmaceutical Packaging Services Complete primary and secondary pharmaceutical packaging solutions delivered in conjunction with manufacturing across the Adragos network. Supports prefilled syringe assembly, vial packaging, and finished product configuration.
• Controlled Drugs Handling Services Specialised manufacturing and handling services for controlled substances and narcotics at facilities licensed for narcotics such as the Athens site (clonazepam, phenobarbital, fentanyl) and Livron's narcotics handling capability. Supports pharmaceutical clients requiring scheduled-drug production with full regulatory compliance.
• Drug Stability Testing Services Comprehensive pharmaceutical stability testing services to establish product shelf-life and meet regulatory submission requirements across FDA, EMA, PMDA, and other authorities. Provided as integrated support alongside Adragos manufacturing and analytical development.
• Cold Chain Management Services Temperature-controlled storage and distribution services for sensitive pharmaceutical products, leveraging cold-storage infrastructure such as the Kawagoe facility's large cold storage warehouse. Supports biotech and pharma products requiring strict temperature control across the supply chain.
• Regulatory Affairs Services Regulatory affairs support across development, clinical, and commercial stages including eCTD-format documentation, submission preparation, and liaison with multi-regional authorities (FDA, EMA, PMDA, ANSM, Swissmedic, and others). Helps pharma clients navigate multi-market approval pathways.
• Out Licensing Services Licensing-out services for pharmaceutical products and intellectual property developed at Adragos facilities, enabling partners to bring developed products into additional markets through structured licensing arrangements.

Quantifiable outcome

• 150 million prefilled syringes per year capacity at Maisons-Alfort facility
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered significant.

• Towa Pharmaceutical (東和약품)significantStrategic or Co-development Partner · 1 January 2025Adragos Pharma Kawagoe signed a basic agreement for strategic collaboration with Towa Pharmaceutical, strengthening partnership for Japanese pharmaceutical manufacturing.
• Colonis PharmasignificantStrategic or Co-development PartnerLong-standing partnership strengthened between Adragos Pharma and Colonis Pharma for pharmaceutical development and manufacturing collaboration.

Scale indicators10 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Aenova Group: European CDMO offering oral solids, semi-solids and sterile liquids across multiple sites; comparable to Adragos' Leipzig, Livron and Maisons-Alfort footprint and similar mid-cap, multi-site profile.
• Delpharm: European CDMO focused on sterile injectables, oral solids and semi-solids with multiple manufacturing sites; directly comparable size, geography and service mix to Adragos.
• Rentschler Biopharma: European biopharma CDMO focused on complex biologics, cell and gene therapy and fill-finish — overlapping with Adragos' Athens HPAPI and Halden sterile capabilities for biotech clients.
• Recipharm: Private European CDMO (EQT-owned) with broad sterile and oral solid capabilities across many sites; competes head-to-head with Adragos in fill-finish, oral solids and semi-solids for European pharma clients.
• Siegfried Holding: Swiss-listed CDMO covering APIs through finished dosage forms including sterile and oral solids; comparable integrated offering and similar European base of operations.
• Vetter Pharma: Family-owned German CDMO specializing in sterile injectables, prefilled syringes and lyophilized vials — directly overlapping with Adragos' Maisons-Alfort and Jura capabilities and targeting the same biotech and specialty-pharma clients.

Broad incumbents

• Catalent (Novo Holdings): Global, multi-modality CDMO incumbent with large sterile injectable and oral solid capacity; competes with Adragos on large-scale biotech outsourcing deals where Adragos is one of many options.
• Lonza Group: Swiss-listed global CDMO leader in biologics, small molecules and sterile manufacturing; sets the benchmark for scale and capability against which mid-caps like Adragos are benchmarked in RFPs.

Emerging players

• Baccinex: Smaller European CDMO focused on sterile injectables and lyophilization; recently acquired by Adragos (Nov 2024), illustrating Adragos' M&A appetite and serving as a smaller-scale sterile injectable comparable.

Regional players

• Fareva: Privately-held French-headquartered CDMO with sterile, semi-solid and oral solid manufacturing across Europe; comparable offering, particularly in France alongside Adragos' Livron and Maisons-Alfort sites.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC5KXqfwBfPyZaApoCCIATAQ
• LinkedInlinkedin.com/company/adragos-pharma

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries7 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adragos Pharma